We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Emerging Markets Power Boston Scientific: Will the Growth Trend Continue?
Read MoreHide Full Article
Key Takeaways
Boston Scientific saw 9.8% operational sales growth in emerging markets in Q1 2025 despite geopolitical risks.
BSX benefits from favorable economic trends, healthcare infrastructure and sustained investment.
BSX competes with ABT and MDT, which also report strong emerging market growth and localization efforts.
Emerging markets remain a vital growth engine for Boston Scientific Corporation (BSX - Free Report) , anchoring the company’s broader international strategy and long-term expansion plans. In the first quarter of 2025, BSX’s emerging market operations, which include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand, and Canada, delivered robust operational sales growth of approximately 9.8% year over year. This performance, fueled by favorable economic trends, expanding healthcare infrastructure, and sustained investment, was delivered despite ongoing geopolitical headwinds. Boston Scientific continues to view these high-potential regions as central to driving adoption of its diverse, minimally invasive medical technologies.
Emerging markets offer strong growth opportunities for the medical device industry, fueled by trends such as preventive healthcare, portable diagnostics and digital health adoption. Per India Brand Equity Foundation, India’s medical device market was valued at $15.35 billion in 2023 and is expected to reach $20.51 billion by 2029 (CAGR 5.35%). China is a key market, supported by its large population, growing middle class and simplified regulatory pathways. Brazil is another major market with a large population and expanding economy, attracting medical device manufacturers. Southeast Asian countries like Thailand, Vietnam and the Philippines are also rising in importance due to rapid economic growth.
Boston Scientific’s strong performance in emerging markets underscores the strategic importance of these regions in driving the company’s long-term international growth. As healthcare needs continue to evolve across these rapidly growing economies, we expect Boston Scientific’s sustained investment, localized strategies, and diversified portfolio position to help capture future growth and maintain its leadership in the global medical device space.
BSX’s Competition in the Emerging Markets
Competition in emerging markets remains intense, with key players like Abbott Laboratories (ABT - Free Report) and Medtronic (MDT - Free Report) actively expanding their global reach.
Abbott, which derives over 60% of its total revenues from outside the United States, has shown consistent strength in emerging economies. In the first quarter of 2025, its Established Pharmaceuticals Division (“EPD”), focused almost entirely on emerging markets, posted high single-digit organic growth, driven by strong demand in several countries across Asia, Latin America and the Middle East. Abbott continues to localize its branded generics product portfolio to address regional healthcare needs.
Similarly, Medtronic generated nearly 49% of its revenues from international markets in the fourth quarter of fiscal 2025, underscoring its global reach. The company’s emerging market business grew in the mid-single digits during the quarter, with notable strength in India, Southeast Asia and Eastern Europe. Medtronic’s strategy in these regions centers on expanding access to advanced medical technologies and addressing unmet clinical needs through localized engagement and tailored product offerings.
BSX’s Price Performance, Valuation and Estimates
Shares of Boston Scientific have gained 35.8% in the past year compared with the industry’s growth of 9.6%. The S&P 500 composite also grew 12.2% in the same period.
Image Source: Zacks Investment Research
From a valuation standpoint, BSX trades at a forward price-to-earnings ratio of 33.69, above the industry’s 21.73.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for BSX’s earnings has been on the rise over the past 60 days.
Image: Bigstock
Emerging Markets Power Boston Scientific: Will the Growth Trend Continue?
Key Takeaways
Emerging markets remain a vital growth engine for Boston Scientific Corporation (BSX - Free Report) , anchoring the company’s broader international strategy and long-term expansion plans. In the first quarter of 2025, BSX’s emerging market operations, which include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand, and Canada, delivered robust operational sales growth of approximately 9.8% year over year. This performance, fueled by favorable economic trends, expanding healthcare infrastructure, and sustained investment, was delivered despite ongoing geopolitical headwinds. Boston Scientific continues to view these high-potential regions as central to driving adoption of its diverse, minimally invasive medical technologies.
Emerging markets offer strong growth opportunities for the medical device industry, fueled by trends such as preventive healthcare, portable diagnostics and digital health adoption. Per India Brand Equity Foundation, India’s medical device market was valued at $15.35 billion in 2023 and is expected to reach $20.51 billion by 2029 (CAGR 5.35%). China is a key market, supported by its large population, growing middle class and simplified regulatory pathways. Brazil is another major market with a large population and expanding economy, attracting medical device manufacturers. Southeast Asian countries like Thailand, Vietnam and the Philippines are also rising in importance due to rapid economic growth.
Boston Scientific’s strong performance in emerging markets underscores the strategic importance of these regions in driving the company’s long-term international growth. As healthcare needs continue to evolve across these rapidly growing economies, we expect Boston Scientific’s sustained investment, localized strategies, and diversified portfolio position to help capture future growth and maintain its leadership in the global medical device space.
BSX’s Competition in the Emerging Markets
Competition in emerging markets remains intense, with key players like Abbott Laboratories (ABT - Free Report) and Medtronic (MDT - Free Report) actively expanding their global reach.
Abbott, which derives over 60% of its total revenues from outside the United States, has shown consistent strength in emerging economies. In the first quarter of 2025, its Established Pharmaceuticals Division (“EPD”), focused almost entirely on emerging markets, posted high single-digit organic growth, driven by strong demand in several countries across Asia, Latin America and the Middle East. Abbott continues to localize its branded generics product portfolio to address regional healthcare needs.
Similarly, Medtronic generated nearly 49% of its revenues from international markets in the fourth quarter of fiscal 2025, underscoring its global reach. The company’s emerging market business grew in the mid-single digits during the quarter, with notable strength in India, Southeast Asia and Eastern Europe. Medtronic’s strategy in these regions centers on expanding access to advanced medical technologies and addressing unmet clinical needs through localized engagement and tailored product offerings.
BSX’s Price Performance, Valuation and Estimates
Shares of Boston Scientific have gained 35.8% in the past year compared with the industry’s growth of 9.6%. The S&P 500 composite also grew 12.2% in the same period.
Image Source: Zacks Investment Research
From a valuation standpoint, BSX trades at a forward price-to-earnings ratio of 33.69, above the industry’s 21.73.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for BSX’s earnings has been on the rise over the past 60 days.
Image Source: Zacks Investment Research
BSX stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.